+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast to 2030- Product Image
Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast to 2030- Product Image
Sale

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715593
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neglected Tropical Diseases Diagnosis Market grew from USD 7.04 billion in 2024 to USD 7.47 billion in 2025. It is expected to continue growing at a CAGR of 5.89%, reaching USD 9.94 billion by 2030.

Pioneering Diagnostics Strategies to Confront Neglected Tropical Diseases

Neglected tropical diseases continue to impose a heavy burden on vulnerable populations across the globe, with millions lacking access to timely and accurate diagnosis. Advances in diagnostic technologies and growing global collaboration have paved the way for breakthroughs in disease detection, yet significant barriers remain. This summary sets the context by examining the critical need for improved diagnostic solutions that can be deployed in low-resource settings and integrated seamlessly into existing healthcare infrastructures.

Through an in-depth review of recent innovations and market drivers, this section outlines why enhancing diagnostic capacity is central to achieving disease control and elimination goals. By understanding the current state of testing modalities, funding landscapes, and implementation challenges, stakeholders can better align resources to bridge diagnostic gaps. This introduction lays the groundwork for exploring transformative shifts, regulatory influences, and strategic segmentation that shape the fragmented yet rapidly evolving ecosystem of neglected tropical disease diagnostics.

Emerging Forces Reshaping the Neglected Disease Diagnostic Landscape

The diagnostic landscape for neglected tropical diseases has undergone rapid transformation driven by technological convergence and shifting public health priorities. Molecular assays once confined to high-resource laboratories are now being adapted into portable platforms, enabling point-of-care testing in remote areas. Immunoassay innovations, such as chemiluminescence and enzyme-linked formats, are delivering heightened sensitivity and specificity while reducing time-to-result.

Simultaneously, microscopy techniques have been revitalized through digital imaging and fluorescence enhancements, allowing field technicians to identify pathogens with greater accuracy. Rapid diagnostic tests have become indispensable tools for screening and surveillance, bridging the gap between centralized laboratories and community health initiatives. These technological advancements are complemented by a surge in public-private partnerships and donor-funded programs, facilitating the translation of laboratory breakthroughs into field-ready solutions. As data-driven decision-making gains prominence, integrated software platforms are emerging to consolidate test results, streamline workflows, and inform policy-level interventions.

Navigating the Ripple Effects of US Tariff Policies on Diagnostics

Recent tariff adjustments instituted by the United States in 2025 have introduced new headwinds for manufacturers and suppliers of diagnostic equipment and reagents. Import levies on critical components such as polymerase chain reaction kits, assay reagents, and imaging devices have driven up costs for laboratories and healthcare providers reliant on global supply chains. These increased expenses threaten to delay procurement cycles and limit the rollout of advanced diagnostic platforms in resource-constrained settings.

In response, organizations are recalibrating sourcing strategies by diversifying supplier portfolios and exploring regional manufacturing partnerships to mitigate exposure to tariff volatility. Collaborative agreements between diagnostic developers and local contract manufacturers are gaining traction, enabling a portion of production to occur in tariff-free zones. Additionally, stakeholders are accelerated efforts to secure bulk purchasing agreements and multi-year procurement contracts, locking in more predictable pricing structures. Although these measures cannot fully offset the added financial burden, they represent proactive steps toward preserving access to essential diagnostic tools amid shifting trade policies.

In-Depth Segmentation Reveals Critical Diagnostic Market Dynamics

A nuanced understanding of the market emerges when dissecting the ecosystem by technology, disease type, end user, application and sample type. In terms of technology, established immunoassays encompass chemiluminescence assays and enzyme-linked immunosorbent assays, complemented by microscopy techniques that leverage both fluorescence and light microscopy. Molecular diagnostics continue to bifurcate into isothermal amplification and polymerase chain reaction methods, while rapid diagnostic tests rely on either antibody or antigen detection.

When considering disease type, Chagas diagnostics employ both enzyme-linked immunosorbent assays and polymerase chain reaction to confirm infection. Leishmaniasis testing differentiates between cutaneous and visceral forms, each with tailored assay protocols. Lymphatic filariasis detection spans antibody screening and immunochromatographic tests, whereas onchocerciasis identification uses polymerase chain reaction alongside traditional skin snip microscopy. Schistosomiasis monitoring integrates stool microscopy and urine antigen testing to capture different stages of infection.

End users range from community health centers and primary care clinics to independent and reference laboratories, private and public hospitals, as well as research institutes driving innovation. In practice, confirmatory testing may occur in high-throughput laboratories or at the point of care, whereas screening initiatives include community campaigns and mass drug administration contexts. Surveillance activities encompass epidemiological tracking and post-elimination monitoring efforts.

Sample type further refines market dynamics. Blood specimens, whether serum or whole blood, constitute the backbone of many assays. Stool samples processed via concentration or direct smear techniques remain essential for parasitic diagnostics. Tissue analyses rely on biopsy and skin snip methods, while urine testing can be performed through concentrated or direct urine assays. This segmentation framework illuminates unmet needs and underscores opportunities for targeted product development and market entry.

Regional Variations Driving Diagnostic Priorities and Investments

Regional nuances significantly influence the adoption and deployment of neglected tropical disease diagnostics. In the Americas, concerted public health campaigns and robust donor funding have bolstered community outreach programs, with Brazil and other high-burden countries leading efforts in field diagnostics and capacity building. Governments are increasingly integrating rapid diagnostic tests into mobile clinics and remote health posts to enhance early detection.

Across Europe, the Middle East and Africa, the landscape is heterogenous. Western Europe contributes through research collaborations and regulatory expertise, while emerging innovation hubs in West Africa are advancing both microscopy and molecular platforms. In the Middle East, growing investments in healthcare infrastructure are opening new channels for technology transfer. Sub-Saharan Africa remains at the epicenter of disease burden, where partnerships between governments, NGOs and private entities drive tailored screening and surveillance initiatives.

Within the Asia-Pacific region, endemic hotspots in South and Southeast Asia sustain high demand for reliable diagnostic solutions. National programs in India and neighboring countries prioritize scalable, cost-effective tests, and regulatory agencies are streamlining approval pathways. The region’s manufacturing capabilities are also expanding, positioning it as a potential production nexus for both regional and global supply chains.

Competitive Landscape Highlights Key Diagnostic Innovators

The competitive landscape is defined by a mix of global diagnostics giants and specialized innovators. Leading multinational corporations are leveraging their extensive distribution networks to introduce multiplex and next-generation molecular platforms into endemic regions. Strategic acquisitions have enabled some players to integrate complementary technologies, bolstering their portfolios with both laboratory-based and point-of-care offerings.

Mid-tier companies with focused expertise in parasitology assays are differentiating through proprietary chemistries and miniaturized instrumentation tailored for on-site testing. Collaborative alliances between academia and small-to-mid-size enterprises are also gaining momentum, accelerating the translation of novel biomarkers and digital reporting tools. Meanwhile, contract research organizations and regional distributors are emerging as critical partners, facilitating localized manufacturing, regulatory navigation and after-sales support.

Strategic Actions to Accelerate Progress in Disease Detection

Industry leaders can seize opportunities by prioritizing the development of multiplex platforms capable of detecting multiple pathogens from a single sample. Strengthening supply chain resilience through diversification of suppliers and strategic stockpiling of critical reagents will buffer against trade disruptions and tariff fluctuations. Establishing public-private partnerships with government agencies and non-profit organizations can expedite field validation and adoption of new diagnostics.

Investing in local manufacturing and assembly facilities can reduce lead times and create cost efficiencies, especially when aligned with regional regulatory frameworks. Embracing digital health solutions, including mobile data collection and tele-microscopy, will streamline reporting and enable real-time surveillance. Finally, capacity building through training programs for laboratory technicians and community health workers remains essential for ensuring accurate and reliable test deployment.

Rigorous Methodological Framework Underpinning Market Insights

This analysis synthesizes insights from an extensive secondary research phase, encompassing peer-reviewed publications, regulatory agency filings and publicly available corporate disclosures. Primary research included structured interviews with key opinion leaders in parasitology, diagnostic developers and procurement specialists. Data triangulation techniques were applied to reconcile discrepancies and validate emerging trends.

A multi-step vetting process involved advisory panel reviews and expert workshops to refine market definitions, segmentation criteria and methodological assumptions. The study framework integrated both qualitative and quantitative analyses, with rigorous quality checks at each stage to ensure data integrity. Geographic and application-level breakdowns were derived using proprietary models calibrated against historical adoption rates, while competitive positioning was assessed through a benchmark analysis of product portfolios and strategic initiatives.

Converging Insights Point to a Transformation in Disease Diagnostics

As the diagnostic landscape for neglected tropical diseases continues to evolve, stakeholders must navigate technological, regulatory and economic complexities with agility. Cross-sector collaboration, coupled with targeted investments in next-generation platforms, holds the key to overcoming persistent diagnostic barriers. The insights presented here chart a course for stakeholders to align R&D, manufacturing and policy efforts toward a unified goal: accessible, accurate and timely diagnosis for every community in need.

By leveraging segmentation, regional understanding and competitive intelligence, decision-makers can sharpen their strategies and accelerate impact. The path forward demands coordination across disciplines and geographies, yet the potential public health gains are profound. With collective commitment and strategic execution, the promise of disease control and eventual elimination moves within reach.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Immunoassays
      • Chemiluminescence Assay
      • Enzyme Linked Immunosorbent Assay
    • Microscopy
      • Fluorescence Microscopy
      • Light Microscopy
    • Molecular Diagnostics
      • Isothermal Amplification
      • Polymerase Chain Reaction
    • Rapid Diagnostic Tests
      • Antibody Detection
      • Antigen Detection
  • Disease Type
    • Chagas Disease
      • Enzyme Linked Immunosorbent Assay
      • Polymerase Chain Reaction
    • Leishmaniasis
      • Cutaneous Leishmaniasis Tests
      • Visceral Leishmaniasis Tests
    • Lymphatic Filariasis
      • Antibody Detection Test
      • Immunochromatographic Test
    • Onchocerciasis
      • Polymerase Chain Reaction
      • Skin Snip Microscopy
    • Schistosomiasis
      • Stool Microscopy
      • Urine Antigen Test
  • End User
    • Clinics
      • Community Health Centers
      • Primary Care Clinics
    • Diagnostic Laboratories
      • Independent Laboratories
      • Reference Laboratories
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Research Institutes
  • Application
    • Confirmatory Testing
      • Laboratory Confirmation
      • Point Of Care Confirmation
    • Screening
      • Community Screening
      • Mass Drug Administration Screening
    • Surveillance
      • Epidemiological Surveillance
      • Post Elimination Surveillance
  • Sample Type
    • Blood
      • Serum Plasma
      • Whole Blood
    • Stool
      • Concentration Technique
      • Direct Smear
    • Tissue
      • Biopsy
      • Skin Snip
    • Urine
      • Concentrated Urine Test
      • Direct Urine Test
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioMérieux SA
  • QIAGEN GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Coris BioConcept SA

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neglected Tropical Diseases Diagnosis Market, by Technology
8.1. Introduction
8.2. Immunoassays
8.2.1. Chemiluminescence Assay
8.2.2. Enzyme Linked Immunosorbent Assay
8.3. Microscopy
8.3.1. Fluorescence Microscopy
8.3.2. Light Microscopy
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. Polymerase Chain Reaction
8.5. Rapid Diagnostic Tests
8.5.1. Antibody Detection
8.5.2. Antigen Detection
9. Neglected Tropical Diseases Diagnosis Market, by Disease Type
9.1. Introduction
9.2. Chagas Disease
9.2.1. Enzyme Linked Immunosorbent Assay
9.2.2. Polymerase Chain Reaction
9.3. Leishmaniasis
9.3.1. Cutaneous Leishmaniasis Tests
9.3.2. Visceral Leishmaniasis Tests
9.4. Lymphatic Filariasis
9.4.1. Antibody Detection Test
9.4.2. Immunochromatographic Test
9.5. Onchocerciasis
9.5.1. Polymerase Chain Reaction
9.5.2. Skin Snip Microscopy
9.6. Schistosomiasis
9.6.1. Stool Microscopy
9.6.2. Urine Antigen Test
10. Neglected Tropical Diseases Diagnosis Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Community Health Centers
10.2.2. Primary Care Clinics
10.3. Diagnostic Laboratories
10.3.1. Independent Laboratories
10.3.2. Reference Laboratories
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
10.5. Research Institutes
11. Neglected Tropical Diseases Diagnosis Market, by Application
11.1. Introduction
11.2. Confirmatory Testing
11.2.1. Laboratory Confirmation
11.2.2. Point of Care Confirmation
11.3. Screening
11.3.1. Community Screening
11.3.2. Mass Drug Administration Screening
11.4. Surveillance
11.4.1. Epidemiological Surveillance
11.4.2. Post Elimination Surveillance
12. Neglected Tropical Diseases Diagnosis Market, by Sample Type
12.1. Introduction
12.2. Blood
12.2.1. Serum Plasma
12.2.2. Whole Blood
12.3. Stool
12.3.1. Concentration Technique
12.3.2. Direct Smear
12.4. Tissue
12.4.1. Biopsy
12.4.2. Skin Snip
12.5. Urine
12.5.1. Concentrated Urine Test
12.5.2. Direct Urine Test
13. Americas Neglected Tropical Diseases Diagnosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Neglected Tropical Diseases Diagnosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Neglected Tropical Diseases Diagnosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche AG
16.3.2. Abbott Laboratories
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. Danaher Corporation
16.3.5. bioMérieux SA
16.3.6. QIAGEN GmbH
16.3.7. Becton, Dickinson and Company
16.3.8. Bio-Rad Laboratories, Inc.
16.3.9. Hologic, Inc.
16.3.10. Coris BioConcept SA
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET MULTI-CURRENCY
FIGURE 2. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET MULTI-LANGUAGE
FIGURE 3. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LABORATORY CONFIRMATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POINT OF CARE CONFIRMATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MASS DRUG ADMINISTRATION SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POST ELIMINATION SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SERUM PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONCENTRATION TECHNIQUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIRECT SMEAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONCENTRATED URINE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIRECT URINE TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 138. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 140. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 141. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 142. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 143. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 145. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 146. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 147. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 148. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 149. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 151. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 152. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 155. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 156. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 157. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 158. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 159. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 160. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 161. CANADA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 162. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 165. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 169. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 176. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 179. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 180. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 182. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 183. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 184. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 185. MEXICO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 207. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 208. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 209. BRAZIL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 221. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 223. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 224. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 227. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 228. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 229. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 230. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 231. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 232. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 233. ARGENTINA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2030 (USD MILLION)
TABLE 266. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2030 (USD MILLION)
TABLE 268. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2030 (USD MILLION)
TABLE 270. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TISSUE, 201

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neglected Tropical Diseases Diagnosis market report include:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioMérieux SA
  • QIAGEN GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Coris BioConcept SA

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.94 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease, By Diagnostic Method, By Service Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease, By Diagnostic Method, By Service Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Neglected Tropical Diseases Diagnosis - Global Strategic Business Report - Product Image

Neglected Tropical Diseases Diagnosis - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Neglected Tropical Diseases Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neglected Tropical Diseases Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Neglected Tropical Diseases Diagnosis Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Neglected Tropical Diseases Diagnosis Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 94 Pages
  • Global
From
Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10 - Product Image

Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10

  • Book

About the Neglected Tropical Diseases Diagnosis Market

Neglected Tropical Diseases (NTDs) Diagnosis is a subset of the Infectious Disease Testing market. NTDs are a group of diseases that disproportionately affect the world’s poorest populations, and are caused by a variety of pathogens, including bacteria, viruses, and parasites. Diagnosis of NTDs is typically done through a combination of clinical symptoms, laboratory tests, and imaging. Diagnostic tests for NTDs are often limited in availability and accuracy, and are often expensive and difficult to access in resource-limited settings. In recent years, there has been an increased focus on the development of new diagnostic tests for NTDs, with the aim of improving access to diagnosis and treatment. This has led to the emergence of a number of companies offering NTD diagnostic tests, including Cepheid, BioMérieux, and Qiagen. Other companies, such as Alere, have developed point-of-care tests for NTDs, which can provide rapid diagnosis in resource-limited settings. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.